Results 1 to 10 of about 24,935 (185)

Oseltamivir for influenza [PDF]

The Lancet, 2015
124 www.thelancet.com Vol 387 January 9, 2016 declare “no competing interests”, but Dobson’s salary was supported by Roche during the analysis and Pocock told a journalist that he received research funds from Gilead and Genentech. Also, Richard Whitley does not inform readers that Gilead Sciences is the patent holder for oseltamivir so readers can ...
Peter, Doshi, Carl, Heneghan, Tom, Jefferson   +2 more
  +14 more sources

Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. [PDF]

PLoS ONE, 2007
Oseltamivir is the main antiviral for treatment and prevention of pandemic influenza. The increase in oseltamivir resistance reported recently has therefore sparked a debate on how to use oseltamivir in non pandemic influenza and the risks associated ...
Jerker Fick, Rickard H Lindberg, Mats Tysklind, Paul D Haemig, Jonas Waldenström, Anders Wallensten, Björn Olsen   +6 more
doaj   +1 more source

Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. [PDF]

PLoS Pathogens, 2010
Influenza viruses resistant to antiviral drugs emerge frequently. Not surprisingly, the widespread treatment in many countries of patients infected with 2009 pandemic influenza A (H1N1) viruses with the neuraminidase (NA) inhibitors oseltamivir and ...
Maki Kiso, Kyoko Shinya, Masayuki Shimojima, Ryo Takano, Kei Takahashi, Hiroaki Katsura, Satoshi Kakugawa, Mai Thi Quynh Le, Makoto Yamashita, Yousuke Furuta, Makoto Ozawa, Yoshihiro Kawaoka   +11 more
doaj   +1 more source

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. [PDF]

PLoS ONE, 2017
Human carboxylesterase 1 (CES1) is a serine esterase that hydrolyses various exogenous and endogenous compounds including oseltamivir, a prodrug used to treat influenza. A novel CES1 c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease
Jaeseong Oh, SeungHwan Lee, Howard Lee, Joo-Youn Cho, Seo Hyun Yoon, In-Jin Jang, Kyung-Sang Yu, Kyoung Soo Lim   +7 more
doaj   +1 more source

The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study

Saudi Pharmaceutical Journal, 2023
Background: Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, the evidence about using oseltamivir in critically ill patients with severe COVID-19 remains scarce.
Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Meshal S. Alotaibi, Noura A. Alrakban, Ragia H. Ghoneim, Ramesh Vishwakarma, Abdulrahman I. Al Shaya, Shmeylan Al Harbi, Jawaher Gramish, Dahlia M. Almutairi, Ghada Alqannam, Faisal F. Alamri, Abdullah F. Alharthi, Mashael Alfaifi, Abdullah Al Amer, Abeer A. Alenazi, Norah Bin Aydan, Mai Alalawi, Khalid Al Sulaiman   +19 more
doaj   +1 more source

A Practical Synthesis of (−)‐Oseltamivir [PDF]

Angewandte Chemie, 2007
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Nobuhiro, Satoh, Takahiro, Akiba, Satoshi, Yokoshima, Tohru, Fukuyama   +3 more
openaire   +2 more sources

Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis

Frontiers in Pharmacology, 2022
Background: As a cause of respiratory tract infections in humans, influenza remains with high morbidity and mortality, with associated significant healthcare burden and increased financial burden.
Yingying Peng, Yingying Peng, Zhe Chen, Huanmin Li, Huanmin Li, Yaowei Han, Yaowei Han, Dan Sun, Dan Sun, Yanjiao Li, Yanjiao Li, Xiaoxia Wu, Xiaoxia Wu, Hongxiang Chen, Hongxiang Chen, Xinmin Li, Xinmin Li   +16 more
doaj   +1 more source

Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs.

PLoS Computational Biology, 2022
Oseltamivir is a widely used influenza virus neuraminidase (NA) inhibitor that prevents the release of new virus particles from host cells. However, oseltamivir-resistant strains have emerged, but effective drugs against them have not yet been developed.
Jiaye Tao, Heping Wang, Wenjian Wang, Na Mi, Wei Zhang, Qiujia Wen, Jiajing Ouyang, Xinyun Liang, Min Chen, Wentao Guo, Guoming Li, Jun Liu, Hanning Zhao, Xin Wang, Xuemeng Li, Shengjun Feng, Xinguang Liu, Zhiwei He, Zuguo Zhao   +18 more
doaj   +1 more source

Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis. [PDF]

PLoS ONE, 2016
BACKGROUND:Influenza is a common viral respiratory infection that causes epidemics and pandemics in the human population. Oseltamivir is a neuraminidase inhibitor-a new class of antiviral therapy for influenza.
Kunling Shen, Tengbin Xiong, Seng Chuen Tan, Jiuhong Wu   +3 more
doaj   +1 more source

Evaluating the effects of oseltamivir phosphate on platelet counts: a retrospective review

Platelets, 2020
Desialylation of platelets results in platelet clearance by the Ashwell-Morrell Receptors (AMR) found on hepatocytes. Studies suggest that oseltamivir phosphate inhibits human sialidases, enzymes responsible for desialylation, extending the lifespan of ...
Hila Shaim, Peter McCaffrey, Judy A Trieu, Abe DeAnda, Sean G. Yates   +4 more
doaj   +1 more source